Experimental treatment may slow disability progression in progressive MS

A new oral therapy called vidofludimus calcium could offer hope to people living with progressive forms of multiple sclerosis (MS).

In a recent clinical trial called CALLIPER, the treatment was shown to reduce the risk of confirmed disability worsening and slow brain shrinkage when compared to a placebo. The trial involved 467 adults with progressive MS who hadn’t had a relapse in the two years before joining the study.

Also known as IMU-838, the therapy was taken once daily and continued to be safe and well tolerated. What’s particularly encouraging is that benefits were also seen in people without active inflammation – a group that often sees limited results from current treatments.

Vidofludimus calcium works by targeting overactive immune cells, helping to reduce inflammation. It also activates a protein linked to protecting the nervous system, suggesting it may offer more than just immune control.

These early findings are promising, but more research will be needed to confirm the therapy’s long-term benefits.